Human myeloma RPMI8226 cells and normal cells have different sensitivity to bisilicate silver nanoparticles in vitro

Abstract

Introduction. Silver nanoparticles due to its pronounced cytotoxicity are regarded as promising agent for anticancer therapy. Determination of normal and transformed cells sensitivity to silver nanoparticles can be the basis for the application as an adjuvant cancer treatment. The objective of the study was to investigate influence of atomic clusters of Argentum (ACA) in the form of silver bisilicate nanoparticles colloid solution on viability and proliferation of human myeloma cell line, mesenchymal stromal cells and blood lymphocytes. Material and methods. Cell viability was evaluated by MTT and LDH assay. Cell proliferation was evaluated by flow cytometry. Results. It was found that ACA had dose-depending cytotoxicity toward all investigated cell types, but normal and transformed cells varied significantly in the sensitivity to nanoparticles. IC50 for myeloma cell line RPMI8226 was 1,75 µg/ml. For MSCs of different origin IC50 was in the range of 12 to 16 µg/ml. ACA in concentration from 2 to 3 µg/ml induced RPMI8226 cells metabolic disruption and death without influence on viability and cell cycle of mesenchymal stromal cells and blood lymphocytes. Conclusion. Results of work has shown distinct differences in sensitivity to ACA between myeloma cells, mesenchymal stromal cells and blood lymphocytes. The optimal range of ACA concentration with anticancer effect without cytotoxic influence on normal cells has been determined in vitro.